


Toxicological Profile for Acetone

June 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
June 2022	Final toxicological profile released
July 2021	Draft for public comment toxicological profile released
August 2011	Addendum to the toxicological profile released
May 1994	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Obaid Faroon, D.V.M., Ph.D. (Lead)
Mike Fay, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Ryan Klein, Ph.D.
Rebecca Gray, M.P.H.
Andrea Chiger, M.P.H.
Kaley Beins, M.P.H.
Hannah Derrick, B.S.
Kerry Diskin, Ph.D.
Mary Juergens, M.P.H.

Abt Associates, Rockville, MD

Julie M. Klotzbach, Ph.D.
Ramsey D. Hanna

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA.

PEER REVIEWERS

1. Leena Nylander-French, Ph.D.; Professor, Department of Environmental Sciences and Engineering; Director, NC Occupational Safety and Health Education and Research Center; Director, Occupational Exposure Science and Industrial Hygiene Program; University of North Carolina at Chapel Hill Gillings School of Global Public Health; Chapel Hill, North Carolina
2. Gunnar Johanson, Ph.D.; Professor of Occupational Toxicology and Risk Assessment; Institute of Environmental Medicine; Karolinska Institutet; Stockholm, Sweden
3. Andrew Patterson, Ph.D.; Tombrós Early Career Professor; Professor of Molecular Toxicology; Professor of Biochemistry & Molecular Biology; Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary and Biomedical Sciences; Pennsylvania State University; University Park, Pennsylvania

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD.....	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS.....	vi
CONTENTS.....	viii
LIST OF FIGURES	x
LIST OF TABLES.....	xi
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs).....	7
CHAPTER 2. HEALTH EFFECTS.....	10
2.1 INTRODUCTION.....	10
2.2 DEATH	43
2.3 BODY WEIGHT.....	44
2.4 RESPIRATORY	45
2.5 CARDIOVASCULAR.....	49
2.6 GASTROINTESTINAL.....	51
2.7 HEMATOLOGICAL	52
2.8 MUSCULOSKELETAL	54
2.9 HEPATIC.....	55
2.10 RENAL	58
2.11 DERMAL.....	61
2.12 OCULAR	62
2.13 ENDOCRINE.....	64
2.14 IMMUNOLOGICAL	64
2.15 NEUROLOGICAL.....	65
2.16 REPRODUCTIVE	71
2.17 DEVELOPMENTAL.....	74
2.18 OTHER NONCANCER.....	75
2.19 CANCER.....	76
2.20 GENOTOXICITY	77
2.21 MECHANISM OF ACTION	81
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	83
3.1 TOXICOKINETICS.....	83
3.1.1 Absorption.....	84
3.1.2 Distribution	89
3.1.3 Metabolism.....	91
3.1.4 Excretion	97
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	104
3.1.6 Animal-to-Human Extrapolations	105
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE... 106	106

3.3	BIOMARKERS OF EXPOSURE AND EFFECT	108
3.3.1	Biomarkers of Exposure.....	109
3.3.2	Biomarkers of Effect.....	115
3.4	INTERACTIONS WITH OTHER CHEMICALS	117
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		134
4.1	CHEMICAL IDENTITY	134
4.2	PHYSICAL AND CHEMICAL PROPERTIES	134
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE.....		136
5.1	OVERVIEW	136
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	139
5.2.1	Production	139
5.2.2	Import/Export.....	139
5.2.3	Use	140
5.2.4	Disposal.....	140
5.3	RELEASES TO THE ENVIRONMENT	141
5.3.1	Air	141
5.3.2	Water.....	142
5.3.3	Soil	143
5.4	ENVIRONMENTAL FATE	144
5.4.1	Transport and Partitioning.....	144
5.4.2	Transformation and Degradation	146
5.5	LEVELS IN THE ENVIRONMENT.....	148
5.5.1	Air	149
5.5.2	Water.....	154
5.5.3	Sediment and Soil	159
5.5.4	Other Media	159
5.6	GENERAL POPULATION EXPOSURE.....	160
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	161
CHAPTER 6. ADEQUACY OF THE DATABASE.....		164
6.1	INFORMATION ON HEALTH EFFECTS.....	164
6.2	IDENTIFICATION OF DATA NEEDS	164
6.3	ONGOING STUDIES.....	172
CHAPTER 7. REGULATIONS AND GUIDELINES		173
CHAPTER 8. REFERENCES		175
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR ACETONE.....	B-1
APPENDIX C.	USER'S GUIDE	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E.	GLOSSARY	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to Acetone	3
1-2. Health Effects Found in Humans Following Inhalation Exposure to Acetone.....	4
1-3. Health Effects Found in Humans and Animals Following Oral Exposure to Acetone.....	5
1-4. Summary of Sensitive Targets of Acetone – Inhalation	7
1-5. Summary of Sensitive Targets of Acetone – Oral	8
2-1. Overview of the Number of Studies Examining Acetone Health Effects	13
2-2. Levels of Significant Exposure to Acetone – Inhalation	24
2-3. Levels of Significant Exposure to Acetone – Oral	35
3-1. Proposed Metabolic Pathway for Acetone in Humans	93
5-1. Number of NPL Sites with Acetone Contamination	136
6-1. Summary of Existing Health Effects Studies on Acetone by Route and Endpoint	165

LIST OF TABLES

1-1 Minimal Risk Levels (MRLs) for Acetone.....	9
2-1. Health Effects in Humans Exposed to Acetone.....	14
2-2. Levels of Significant Exposure to Acetone – Inhalation	16
2-3. Levels of Significant Exposure to Acetone – Oral	29
2-4. Levels of Significant Exposure to Acetone – Dermal	40
2-5. Genotoxicity of Acetone <i>In Vitro</i>	79
2-6. Genotoxicity of Acetone <i>In Vivo</i>	81
4-1. Chemical Identity of Acetone.....	134
4-2. Physical and Chemical Properties of Acetone.....	135
5-1. Lowest Limit of Detection Based on Standards	148
5-2. Summary of Environmental Levels of Acetone in the United States	149
5-3. Acetone Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	149
5-4. Percentile Distribution of Annual Mean Acetone Concentrations (ppb Carbon) Measured in Ambient Air at Locations Across the United States	150
5-5. Outdoor Air Monitoring Data for Acetone.....	151
5-6. Indoor Air Monitoring Data for Acetone.....	153
5-7. Maximum Measured Values of Acetone at Selected Hazardous Waste Sites with Potential for Vapor Intrusion.....	155
5-8. Water Monitoring Data for Acetone.....	157
5-9. Drinking Water Monitoring Data for Acetone	158
5-10. Concentrations of Acetone in Human Biomarkers Collected in the United States	161
7-1. Regulations and Guidelines Applicable to Acetone	173